IL314786A - Compounds and radioligands for targeting neurotensin receptor and uses thereof - Google Patents
Compounds and radioligands for targeting neurotensin receptor and uses thereofInfo
- Publication number
- IL314786A IL314786A IL314786A IL31478624A IL314786A IL 314786 A IL314786 A IL 314786A IL 314786 A IL314786 A IL 314786A IL 31478624 A IL31478624 A IL 31478624A IL 314786 A IL314786 A IL 314786A
- Authority
- IL
- Israel
- Prior art keywords
- radioligands
- receptor targeting
- neurotensin receptor
- targeting compounds
- compounds
- Prior art date
Links
- 102000017922 Neurotensin receptor Human genes 0.000 title 1
- 108060003370 Neurotensin receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002287 radioligand Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311621P | 2022-02-18 | 2022-02-18 | |
| PCT/US2023/013314 WO2023158802A1 (en) | 2022-02-18 | 2023-02-17 | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314786A true IL314786A (en) | 2024-10-01 |
Family
ID=87579080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314786A IL314786A (en) | 2022-02-18 | 2023-02-17 | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12145926B2 (enExample) |
| EP (1) | EP4479040A1 (enExample) |
| JP (1) | JP2025506705A (enExample) |
| KR (1) | KR20240150464A (enExample) |
| CN (1) | CN119136796A (enExample) |
| AU (1) | AU2023221977A1 (enExample) |
| CA (1) | CA3243418A1 (enExample) |
| CL (1) | CL2024002422A1 (enExample) |
| IL (1) | IL314786A (enExample) |
| MX (1) | MX2024009858A (enExample) |
| WO (1) | WO2023158802A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023158802A1 (en) | 2022-02-18 | 2023-08-24 | Full-Life Technologies U.S. Inc. | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
| JP2026106435A (ja) * | 2024-12-17 | 2026-06-29 | イーライ リリー アンド カンパニー | ニューロテンシン受容体リガンド |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| DE4307983A1 (de) | 1993-03-13 | 1994-09-15 | Beiersdorf Ag | Wirkstoffe und kosmetische und dermatologische Zubereitungen |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| CA2949936C (en) | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| WO2023158802A1 (en) | 2022-02-18 | 2023-08-24 | Full-Life Technologies U.S. Inc. | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
-
2023
- 2023-02-17 WO PCT/US2023/013314 patent/WO2023158802A1/en not_active Ceased
- 2023-02-17 AU AU2023221977A patent/AU2023221977A1/en active Pending
- 2023-02-17 IL IL314786A patent/IL314786A/en unknown
- 2023-02-17 JP JP2024548610A patent/JP2025506705A/ja active Pending
- 2023-02-17 KR KR1020247030010A patent/KR20240150464A/ko active Pending
- 2023-02-17 CA CA3243418A patent/CA3243418A1/en active Pending
- 2023-02-17 CN CN202380034728.3A patent/CN119136796A/zh active Pending
- 2023-02-17 EP EP23756915.7A patent/EP4479040A1/en active Pending
-
2024
- 2024-03-13 US US18/604,397 patent/US12145926B2/en active Active
- 2024-08-12 MX MX2024009858A patent/MX2024009858A/es unknown
- 2024-08-13 CL CL2024002422A patent/CL2024002422A1/es unknown
- 2024-09-25 US US18/895,915 patent/US20250026739A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023158802A1 (en) | 2023-08-24 |
| CA3243418A1 (en) | 2023-08-24 |
| US20240287046A1 (en) | 2024-08-29 |
| CL2024002422A1 (es) | 2024-12-06 |
| AU2023221977A1 (en) | 2024-08-15 |
| KR20240150464A (ko) | 2024-10-15 |
| US20250026739A1 (en) | 2025-01-23 |
| EP4479040A1 (en) | 2024-12-25 |
| MX2024009858A (es) | 2024-11-08 |
| US12145926B2 (en) | 2024-11-19 |
| CN119136796A (zh) | 2024-12-13 |
| JP2025506705A (ja) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288960A (en) | Radiolabeled compounds targeting the prostate-specific membrane antigen | |
| PL3946464T3 (pl) | Związki i ich koniugaty | |
| EP4061254A4 (en) | Targeting guides | |
| IL310653A (en) | Compounds targeting mutant of p53 | |
| EP3877416A4 (en) | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | |
| MA50100A (fr) | Adn à extrémité fermée (cedna) modifié | |
| EP4039712A4 (en) | CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CLL1 AND ITS USE | |
| EP2125920A4 (en) | HIGH-FUNCTIONAL AMINE COMPOUNDS AND THEIR USE | |
| EP4516316A4 (en) | TARGETING AGENT | |
| EP4051711A4 (en) | ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES | |
| EP4042181A4 (en) | ULTRASONIC DETECTOR | |
| DK4217398T3 (da) | Anti-c-met-antistof-lægemiddelkonjugater | |
| EP3645041A4 (en) | AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES | |
| EP3773670A4 (en) | HSP90 TARGETING CONJUGATES AND FORMULATIONS THEREOF | |
| IL310915A (en) | Herbicidal malonamides | |
| EP3946524A4 (en) | MOVABLE SLEEVE INJECTION ARRANGEMENT | |
| PL3710485T3 (pl) | Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania | |
| IL306141A (en) | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof | |
| EP3856304A4 (en) | ULTRASONIC FOG INHALER | |
| EP3595721A4 (en) | CHIMERA ANTIGEN RECEPTORS FOR TARGETING CD37 | |
| EP3811451A4 (en) | HEART SPECIFIC TARGETING PEPTIDE (CTP), COMPOSITIONS AND USES THEREOF | |
| EP4031218A4 (en) | ULTRASONIC MIST INHALER | |
| EP4407005A4 (en) | HARDENABLE COMPOSITION | |
| EP4209345A4 (en) | HARDENABLE COMPOSITION | |
| EP4177053A4 (en) | CURABLE COMPOSITION |